VAXDYN Company Profile, Contacts & Intelligence

VAXDYN Overview

Headquartered in Seville, Spain, Vaxdyn works with an international network of collaborators in the development of multi-pathogen vaccines for preventing antibiotics-resistant infections in all regions of the world. Our vaccines target high-risk populations, population affected by chronic diseases of the lungs, liver, kidney, immunocompromised by co-morbidities like diabetes or cancer, populations associated with nursing homes and hospital settings, women affected by recurrent urinary-tract infections, or neonates. We are strongly committed to contribute to reducing antibiotic use in the world by following a One-Health approach. Vaxdyn is the first Spanish biotech funded by CARB-X. CARB-X awarded Vaxdyn in 2020 up to US$1.01 million, plus an additional $6.36 million if certain project milestones are met, to develop KapaVax until completion of the first proof of principle in humans (Phase 1). KapaVax is our first multi-valent candidate designed to raise immunity against Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii, the top-3 superbacteria of urgent risk of the list of the World Health Organization (WHO).

Headquarters

Sevilla, Es

Website

www.vaxdyn.com

Industry

Research Services

Founded

2011

NAICS

Scientific Research and Development Services, Research and Development in the Physical, Engineering, and Life Sciences

VAXDYN Contact Intelligence

See which contact channels and departments are represented in the visible AeroLeads data.

VAXDYN People & Org Chart Preview

Sample people records show job titles and whether email or phone data is available without exposing raw contact details.

VAXDYN Workforce Composition

Seniority breakdown across 4 visible profiles.

Compare Similar Companies to VAXDYN

Explore companies in related markets and compare their industry and employee estimates.